Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenovirus in an orthotopic model of advanced lung cancer
Article first published online: 5 FEB 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 6, page 1213, 15 March 2007
How to Cite
Hoffman, R. M. (2007), Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenovirus in an orthotopic model of advanced lung cancer. Cancer, 109: 1213. doi: 10.1002/cncr.22494
- Issue published online: 7 MAR 2007
- Article first published online: 5 FEB 2007
Sarkioja et al.1 have evaluated efficacy of a capsid-modified adenovirus in an orthotopic model of lung cancer by using what they state is a novel animal model and imaging technology.
The authors state that they developed a novel orthotopic model of advanced lung cancer. However, the orthotopic lung cancer model that Sarkioja et al. claim to have developed was first developed by McLemore in the 1980s.2 An improved orthotopic model of lung cancer that is more metastatic and patient-like was developed by our laboratory in the 1990s, including a model that expresses green fluorescent protein (GFP)3 (please see below).
Sarkioja et al. state that they developed a model for longitudinal monitoring of tumor burden over time through monitoring GFP expression. The GFP whole-body imaging technology that Sarkioja et al. claim they developed was developed by our laboratory in 2000.4 Our laboratory also was the first to use GFP imaging models to monitor drug efficacy in real time.5 Although Sarkioja et al. claim to “take pictures” of images, the authors display only pseudo-color images. Sarkioja et al. do not present the original imaging data for reasons they do not explain. Examples of actual fluorescent protein images of drug response from our laboratory can be seen in our article, The multiple uses of fluorescent proteins to visualize cancer in vivo.5
Robert M. Hoffman PhD*, * University of California at San Diego AntiCancer, Inc. San Diego, California.